Lumen Bioscience: Lumen Bioscience granted FDA fast track for C. difficile treatment

Lumen Bioscience has announced that the US Food and Drug Administration (FDA) has granted fast track designation for LMN-201, its biologic drug to treat and prevent C. difficile infection (CDI).